Statin Therapy in Patients With Insulin Resistance

Slides:

Advertisements

Similar presentations

Identify the risk factors, diagnosis and prevalence of diabetes in the United States. Describe the function of the pancreas, the intestines and liver.

Advertisements

Date of download: 7/5/2016 From: Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus:

Statin Myopathy (AHA/ACC/NHLBI)

Question: Could diabetes be drivens by our bones?

Diabetic Dyslipidemia in Practice

Updates and Perspectives in Diabetic Dyslipidemia

Engaging the INSULIN-TREATED T2DM Patient: the Importance of Real-World Data.

Statin Selection in the Elderly

Optimizing Statin Therapy

Diabetes and Risk of CV Outcomes

Statin Selection Aimed to Reduce New-Onset DM Risk:

Program Goals. Inhaled Insulin: Overcoming Past Obstacles With Advances in Understanding.

Patient Presentation. Patient Presentation PRIMO Study Incidence of Muscle Adverse Effects.

Overview of Disparities

The Next Generation of Basal Insulins

ODYSSEY LONG TERM Trial design: Participants with heterozygous familial hypercholesterolemia or high CV risk on statin therapy were randomized to alirocumab.

Metastatic Renal Cell Carcinoma

Obesity and Dyslipidemia: How Would You Treat?

Nilotinib 300 mg bid Nilotinib 400 mg bid Imatinib 400 mg qd n Median

Understanding Statin Metabolism

Panelists. One Size May Not Fit All: A New Aspirin Option for the High-Risk Patient.

Metabolically Healthy Patients With Obesity

بعض النقاط التي تؤخذ في الحسبان عند تقييم الاستثمارات الزراعية

Goals. The Truth About Statins: High vs Moderate Dose for Secondary Prevention of CAD.

Statins and New-Onset Diabetes REAL Updates and Clinical Implications

Statin Class in Session

Diabetes Increases Risk of CVD

Faster-Acting Insulins

Statins and Glucose Metabolism: Are All Agents Alike?

Statin Class in Session

PCP View: ACC/AHA Guidelines: Role of Moderate Intensity Statins

Personalizing Statin Therapy in Patients With HIV

A Journal Club on Lipid Management:

Overview. 5 Things You Need to Know About Statin Selection in Patients With HIV Infection.

% decrease in LDL-C at 24 weeks from baseline

ODYSSEY FH I and II Trial design: Participants with heterozygous familial hypercholesterolemia on statin therapy were randomized to alirocumab 75 mg SQ.

Statins and HIV:.

Radical New Concepts in Lipid Management

New Horizons in Adjunctive Type 1 Diabetes Management With SGLT Inhibitors.

Panelists. Secondary Prevention in Patients With ACS and Diabetes: How Can We Optimize Therapy?

Novel Approaches to T1D Management

Lipid Clinic Challenge

The Cardiologist's Mindset in the Management of Diabetes and Coronary Artery Disease: Today and Tomorrow.

Aspirin and Cardioprevention in 2018

Novel Insulin/GLP-1 Combinations: Of Interest to the Primary Care Physician?

WHAT’S NEW WITH THE TREATMENTS FOR HIGH-RISK DYSLIPIDEMIA?

Definition of Elderly. Advanced Age and CV Risk: To Start or Not to Start a Statin in Older Patients?

Younger Patients With Type 1 Diabetes: Can We Optimize Their Insulin Therapy?

Hepatitis C: After the Diagnosis

Dual SGLT1/SGLT2 Inhibition in T1D

Statins, Obesity, and Hyperlipidemia

VOD/SOS: Aligned Education for Patients and the Interprofessional Team

Glucose Management and Statin Therapy

Add-On Therapy to Insulin in T1DM Management

Goals. The Truth About Statins: High vs Moderate Dose for Secondary Prevention of CAD.

Fasting plasma adiponectin concentration in relation to body mass index (BMI) (A), waist circumference (B), acute insulin response (AIR) (C) and insulin.

New Lipid-Lowering Guidelines

Statins and Glucose Metabolism: An Endocrinology Perspective

Glucose Management and Statin Therapy

Achieving Lipid Targets With PCSK9 Inhibition

Statin Selection in Patients With Pre-Diabetes: Case Considerations

Hyperinsulinemic-euglycemic clamps revealed that obese TPL2KO mice have an improved insulin sensitivity compared with obese WT mice. Hyperinsulinemic-euglycemic.

Hyperinsulinemic-euglycemic clamp–derived insulin sensitivity (glucose disposal), model-derived insulin secretion parameters (sensitivity first-phase insulin.

Plasma glucose (A) and glucose specific activity (B) during euglycemic clamp experiments. Plasma glucose (A) and glucose specific activity (B) during euglycemic.

TG-CRP mice display fasting hyperglycemia, hyperinsulinemia, and insulin resistance. TG-CRP mice display fasting hyperglycemia, hyperinsulinemia, and insulin.

Effect of gonadotropin-releasing-hormone-induced hypogonadism on insulin action as assessed by euglycemic clamp studies in men Subodhsingh Chauhan, M.D.,

Spearman rank order correlation between suppression of hepatic glucose production with low insulin infusion and 30-min change in glucose response in women.

Metabolic Impact of Nonalcoholic Steatohepatitis in Obese Patients

Fresh perspectives ON BASAL Insulins in diabetes care

Insulin secretion (hyperglycemic clamp) (A), insulin sensitivity (hyperinsulinemic-euglycemic clamp) (B), and glucose disposition index (GDI) (C) in adolescents.

Presentation transcript:

Statin Therapy in Patients With Insulin Resistance

Overview: Dr Bays

Risk of Developing NODM Meta-Analysis of Placebo-Controlled Statin Trials

Effect of Statins on Hepatic Fat and Insulin Sensitivity

Risk Factors That Increase Risk of Statin-Promoted Abnormalities in Glucose Metabolism

Effects of Pitavastatin on Insulin Sensitivity and Liver Fat

Assessment of Insulin Sensitivity

Clamp: Gold Standard for Measuring Insulin Sensitivity and Liver Fat

Euglycemic Hyperinsulinemic Clamp Trial Effects of Pitavastatin on Insulin Sensitivity and Liver Fat

How Can We Measure Hepatic Insulin Sensitivity in Vivo?

How Can We Measure Hepatic Insulin Sensitivity in Vivo? (cont)

How Can We Measure Peripheral Insulin Sensitivity in Vivo?

How Can We Measure Hepatic Steatosis?

Patient Selection

Baseline Characteristics

Pitavastatin Has Neutral Effect on FBG Across Dose Range – Meta-Analysis of Patients With and Without Diabetes

Results: Liver Fat

Overall Results of Clamp Study

Patient Reassurance and Study Take-Away

It Takes a Team

Conclusion

Abbreviations

Abbreviations (cont)